U.S. Department of Labor Supports Novartis Sales Reps In Their Overtime Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
The federal government says a district court erred in finding sales reps are outside sales persons exempt from overtime pay requirements.
You may also be interested in...
Sales Reps Overtime Suit Goes To Supreme Court; Could The IMS Win Bite Pharma?
The high court will hear oral arguments on whether sales reps sell drugs or just promote them; Thomas Goldstein, who won a victory for PhRMA in Sorrell v. IMS, is representing the sales reps and former Solicitor General Paul Clement is arguing for GlaxoSmithKline.
Legal & Regulatory News, In Brief
Merck, SciClone join companies under Foreign Corrupt Practices Act investigation: Merck and SciClone reported in recent 10-Q filings with the Securities and Exchange Commission that the Department of Justice and the SEC are investigating their activities overseas to determine if they were in compliance with the Foreign Corrupt Practices Act. Merck said the DoJ and SEC are seeking information about its activities in a number of countries and SciClone said the agencies are investigating the "sale, licensing and marketing of its products in foreign countries, including China." Last year several companies, including Lilly, Bristol-Myers Squibb and AstraZeneca, reported they were under investigation for possible violations of the FCPA, which prohibits U.S. companies from bribing foreign officials for government contracts and other business (1"The Pink Sheet," Aug. 31, 2009)
Legal & Regulatory News, In Brief
Merck, SciClone join companies under Foreign Corrupt Practices Act investigation: Merck and SciClone reported in recent 10-Q filings with the Securities and Exchange Commission that the Department of Justice and the SEC are investigating their activities overseas to determine if they were in compliance with the Foreign Corrupt Practices Act. Merck said the DoJ and SEC are seeking information about its activities in a number of countries and SciClone said the agencies are investigating the "sale, licensing and marketing of its products in foreign countries, including China." Last year several companies, including Lilly, Bristol-Myers Squibb and AstraZeneca, reported they were under investigation for possible violations of the FCPA, which prohibits U.S. companies from bribing foreign officials for government contracts and other business (1"The Pink Sheet," Aug. 31, 2009)